-
Chapter
EXPECT-NLP: An Integrated Pipeline and User Interface for Exploring Patient Preferences Directly from Patient-Generated Text
Understanding patient preferences for drug therapies can help to inform drug development, reimbursement decisions by insurers, and shared decision-making by patients and clinicians. Typically, preferences are ...
-
Article
Open AccessA perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advanc...
-
Article
Develo** Data Sharing Models for Health Research with Real-World Data: A Sco** Review of Patient and Public Preferences
For researchers to realize the benefits of real-world data in healthcare requires broader access to patient data than is currently possible given siloed data systems. To facilitate evidence generation, infrast...
-
Article
Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges
Precision medicine (PM) informed by next-generation sequencing (NGS) poses challenges for health technology assessment (HTA). To date, there has been limited reimbursement of genomic testing with NGS in Canada...
-
Article
Open AccessGenomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values
New clinical genomic assays for lymphoid cancers allow for improved disease stratification and prognostication. At present, clinical implementation has been appropriately limited, owing to a paucity of evidenc...
-
Article
Balancing uncertainty with patient autonomy in precision medicine
By the nature of their unknown pathogenicity, variants of unknown significance (VUS) should not inform clinical decisions for genetic carrier testing; nevertheless, VUS are increasingly returned to patients. W...
